Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST ‐Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation ( BRAVE ) 4 Trial
Key result
The BRAVE 4 trial is designed to evaluate whether prasugrel plus bivalirudin is superior to clopidogrel plus unfractionated heparin for net clinical outcome in STEMI patients undergoing primary PCI.
Why the study?
Does prasugrel plus bivalirudin improve net clinical outcome compared to clopidogrel plus unfractionated heparin in STEMI patients undergoing primary PCI?
Population
STEMI patients with planned primary PCI
Comparison
Prasugrel plus bivalirudin vs Clopidogrel plus unfractionated heparin
Design
Other, randomized, open-label
Authors
Discussion
Loading...
Member takes
Implication
The BRAVE 4 trial is designed to evaluate whether a strategy of prasugrel plus bivalirudin is superior to clopidogrel plus unfractionated heparin for net clinical outcomes in STEMI patients undergoing primary PCI.
Study Design
Type
RCT
Blinding
Open-label
Randomization
Randomized
Multicenter
Yes
Structured PICO
Does prasugrel plus bivalirudin improve net clinical outcome compared to clopidogrel plus unfractionated heparin in STEMI patients undergoing primary PCI?
P
Population
STEMI patients with planned primary percutaneous coronary intervention.
I
Intervention
Prasugrel plus bivalirudin
C
Comparator
Clopidogrel plus unfractionated heparin
O
Outcome
Net clinical outcomecomposite
The BRAVE 4 trial is designed to evaluate whether a strategy of prasugrel plus bivalirudin is superior to clopidogrel plus unfractionated heparin for net clinical outcomes in STEMI patients undergoing primary PCI.
Cite This Study
Schulz et al. (2014) conducted an RCT in ST-segment elevation myocardial infarction (STEMI). Prasugrel plus bivalirudin vs. Clopidogrel plus unfractionated heparin was evaluated on Net clinical outcome. The BRAVE 4 trial is designed to evaluate whether prasugrel plus bivalirudin is superior to clopidogrel plus unfractionated heparin for net clinical outcome in STEMI patients undergoing primary PCI.